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Abstract 
Background: The discovery of novel biomarkers of stroke etiology would be most helpful in management of acute 
ischemic stroke patients. Recently, circular RNAs (circRNAs) have been proposed as candidate biomarkers of neuro‑
logical conditions due to its high stability. circRNAs function as sponges, sequestering miRNAs and are involved in 
most relevant biological functions. Our aim was to identify differentially expressed circRNAs in acute ischemic stroke 
patients according to stroke etiology.
Methods: A comprehensive expression profile of blood circRNAs was conducted by Arraystar Human circRNA arrays 
(13,617 probes) on a discovery cohort of 30 stroke patients with different stroke etiologies by TOAST classification. 
Real‑time quantitative PCR (RT‑qPCR) was used to validate array results in a cohort of 50 stroke patients. Functional 
in silico analysis was performed to identify potential interactions with microRNAs (miRNAs) and pathways underlying 
deregulated circRNAs.
Results: A set of 60 circRNAs were found to be upregulated in atherotrombotic versus cardioembolic strokes (fold‑
change > = 1.5 and p‑value ≤ 0.05). Differential expression of hsa_circRNA_102488, originated from UBA52 gene, was 
replicated in the validation cohort. RNA‑binding proteins (RBPs) sites of hsa_circRNA_102488 clustered around AGO2 
and FUS proteins. Further functional analysis revealed interactions between deregulated circRNAs and a set of miRNAs 
involved in stroke‑related pathways, such as fatty acid biogenesis or lysine degradation.
Conclusion: Different stroke subtypes show specific profiles of circRNAs expression. circRNAs may serve as a new 
source of biomarkers of stroke etiology in acute ischemic stroke patients.
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Introduction
Stroke is a common vascular disease that causes death 
and disability and is therefore a major challenge to cur-
rent healthcare systems [1]. Nowadays, stroke diagnosis 
is still based on clinical criteria and imaging data, so cli-
nicians are able to identify the etiology in about 75–80% 
of stroke cases by following the TOAST classification 
system [2]. In the remaining 20–25% of cases, the exact 
cause is unknown. It has been estimated that in about 
25–30% of these cause-undetermined events, the under-
lying source of stroke could be paroxysmal atrial fibril-
lation (PAF) [1]. However, demonstrating this or other 
causes behind undetermined stroke events still remains 
a challenge in the clinical setting. Therefore, there is 
an increasing need for biomarkers capable of identify-
ing stroke etiology in clinical practice. In recent years, 
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numerous studies have investigated a large amount of 
new blood biomarkers in relation with stroke etiology 
[3–7]. However, low sensitivity and specificity of the 
target biomarkers difficult their translation into clinical 
practice. Thus, the discovery of new molecules to aid the 
diagnosis of stroke etiology would be most helpful in this 
scenario.
By far, proteins represent the most widely studied class 
of molecules in the identification of biomarkers for cere-
brovascular diseases. However, RNA molecules were also 
suggested as candidate stroke biomarkers about a decade 
ago [8, 9]. In particular, brain and blood profiling in rat 
models revealed differential expression of certain micro-
RNAs (miRNAs) after transient focal ischemia [8] and 
blood miRNAs were proposed as diagnostic and prog-
nostic biomarkers in acute stroke patients [9].
Since then, a wide range of RNA species have been 
discovered, including circular RNAs (circRNAs). cir-
cRNAs are endogenous single-stranded RNA mol-
ecules which form a circle through a covalent binding 
[10]. These molecules are evolutionary conserved and 
very abundant in the human transcriptome [11]. cir-
cRNAs display a wide range of regulatory functions in 
RNA biology and gene expression. For instance, some 
circRNAs function as sponges that sequester miRNAs 
or RNA-binding proteins, regulating the expression of 
target genes [12]. In addition, given that circRNAs do 
not have free ends, they are resistant to endonucle-
ase activity and therefore more stable than other lin-
ear RNA species such as messenger RNA (mRNA) or 
even microRNAs (miRNAs) [13]. This features make 
circRNAs promising biomarkers in different medical 
conditions. Indeed, circRNAs have recently been pro-
posed as potential clinical biomarkers for neurologi-
cal disorders [14]. However, comprehensive circRNAs 
expression has not been examined in stroke patients so 
far.
In this study, we have comprehensively profiled circR-
NAs in the peripheral blood of ischemic stroke patients 
during the acute stage. To this end, we used Arraystar 
Human circRNA Array (8 × 15  K, Arraystar), which 
surveys up to 13,617 probes to identify human circR-
NAs, in 30 acute stroke patients with different etiolo-
gies by TOAST classification [2]. As a result, we show 
that distinct circRNAs are differentially expressed in 
atherotrombotic versus cardioembolic stroke patients, 
arising as promising candidate biomarkers of stroke 
etiology.
Methods
Study population
Patients with acute ischemic stroke admitted to 
the emergency department of the Hospital of Nav-
arra within the first 4.5  h after symptoms onset were 
included in the study. Among a cohort of 700 consecu-
tive patients recruited from January 2015 to December 
2016, 30 patients were included in the discovery cohort 
(Table  1) and 50 patients were included in the valida-
tion cohort (Additional file 2: Table S1). All participants 
completely fulfilled the etiology testing protocol (see 
methods below). Informed consent was obtained from 
all participants and the study was approved by the local 
Ethics Committee.
Table 1 Demographic and clinical characteristics of patients
IRQ interquartile range
Atherothrombotic 
(n = 8)
Cardioembolic (n = 14) Undetermined (n = 8) p-value
Age—years, median (IQR) 70 (55–80) 75 (70.5–77) 66.5 (49–77) 0.366
Male, n (%) 7 (87.5) 7 (50) 5 (62.5) 0.214
High blood pressure, n (%) 6 (75) 12 (85.7) 3 (37.5) 0.056
Diabetes mellitus, n (%) 2 (25) 2 (14.3) 2 (25) 0.765
Dyslipidemia, n (%) 3 (37.5) 9 (64.3) 5 (62.5) 0.441
Smoker, n (%) 4 (50) 2 (20) 3 (42.9) 0.38
Cardiopathy, n (%) 3 (37.5) 6 (42.9) 0 (0) 0.093
Atrial fibrillation, n (%) 0 (0) 15 (100) 0 (0) < 0.001***
Peripheral arteropathy, n (%) 2 (25) 0 (0) 0 (0) 0.053
Basal mRankin, median (IQR) 0.5 (0–1) 0 (0–1.25) 0 (0–0.75) 0.565
Basal NIHSS, median (RIQ) 8.5 (5–18) 20 (17–22) 19 (18–20) 0.049*
Significant ipsilateral carotid stenosis (%) 8 (100) 0 (0) 1 (14.3) < 0.001***
Hemorrhagic transformation, n (%) 5 (62.5) 4 (28.6) 2 (25) 0.206
Discharge mRankin, median (IQR) 4.5 (2–6) 4 (2–5) 3 (0.5–5) 0.434
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Clinical, vascular and brain imaging protocol
A detailed history of vascular risk factors including 
hypertension, atrial fibrillation, diabetes mellitus, dys-
lipidemia, tobacco, cardiovascular disease and periph-
eral atherosclerosis was recorded for each patient. In 
order to determine stroke etiology, a set of tests was 
performed including electrocardiogram (EKG), chest 
radiography, complete blood count, blood biochemistry 
analysis, carotid ultrasonography, transcranial doppler 
(TCD) examination, non-contrast cranial tomography 
(CT) at baseline, echocardiogram and 24 h holter moni-
toring. Patients were classified into etiological subgroups 
according to Trial of Org 10172 in Acute Stroke Treat-
ment (TOAST) criteria [2].
Microarray expression of circRNAs
Venous blood samples were drawn from acute stroke 
patients within 24  h after admission. Total RNA was 
isolated from blood samples using miRNeasy Mini kit 
(QIAGEN, Redwood City, CA, USA) which enables 
purification of total RNA, including RNA from approxi-
mately 18 nucleotides upwards, following manufacturer’s 
instructions. Genomic DNA was removed with a recom-
binant DNase (TURBO DNA-free™ Kit, Ambion, Inc., 
Austin, TX, USA). RNA integrity was assessed by elec-
trophoresis on a denaturing agarose gel. Concentration 
of RNA was determined by OD260 using a NanoDrop 
ND-1000 spectrophotometer. Array star Human cir-
cRNA Array V2 analysis (Arraystar, Inc., Rockville, MD, 
USA) of the 30 selected stroke samples was performed 
as follows. Sample labeling and array hybridization 
were completed according to the manufacturer’s proto-
col (Arraystar Inc.). Briefly, 2000 ng of total RNAs were 
digested with RNase R (Epicentre, Inc.) to remove lin-
ear RNAs and enrich circular RNAs. Then, the enriched 
circular RNAs were amplified and transcribed into 
fluorescent cRNA utilizing a random priming method 
(Arraystar Super RNA Labeling Kit; Arraystar). The 
labeled cRNAs were purified by RNeasy Mini Kit (Qia-
gen) and hybridized onto the Arraystar Human circRNA 
Array V2 (8 × 15 K, Arraystar). After having washed the 
slides, the arrays were scanned by the Agilent Scanner 
G2505C (Agilent Technologies, Inc., Santa Clara, CA, 
USA).
circRNAs microarray data
Scanned images were imported into Agilent Feature 
Extraction software (version 11.0.1.1) for raw data extrac-
tion. Quantile normalization of raw data and subsequent 
data processing were performed using the R software 
(R Project for Statistical Computing, Vienna, Austria) 
limma package. Normalized intensity values are shown in 
Additional file 1: Fig. S1. After quantile normalization of 
the raw data, low intensity filtering was performed, and 
those circRNAs in which at least 8 out of 30 samples had 
flags in “P” or “M” (“All Targets Value”) were retained for 
further analyses. Three distinct groups by stroke etiol-
ogy (cardioembolic, atherotrombotic and undetermined) 
were analyzed by pairs, so three different comparisons 
were performed. When comparing two groups of profile 
differences (such as cardioembolic versus atherotrom-
botic), the fold change (FC) (i.e. the ratio of the group 
averages) between the groups for each circRNA was com-
puted. Differentially expressed circRNAs between two 
groups were identified through FC filtering and statisti-
cal significance of the difference between two groups was 
estimated by Student’s t-test. CircRNAs having FC ≥ 1.5 
and p-values ≤ 0.01 were selected as significantly dif-
ferentially expressed. Differentially expressed circRNAs 
with statistical significance between two groups were 
shown by Scatter plots and Volcano plots.
Validation of array results by qPCR
Blood RNA isolated by miRNeasy Mini kit (QIAGEN, 
Redwood City, CA, USA) from the validation cohort 
(n = 50) was used to validate array results. Complemen-
tary DNA (cDNA) was reverse transcribed from 500 ng 
total RNA per sample with  SuperScript® III First-Strand 
Synthesis Reverse Transcriptase (Invitrogen, Carlsbad, 
CA, USA) and primed with random primers. Real time-
qPCR (RT-qPCR) reactions were performed in triplicate 
for each sample using Power  SYBR® Green PCR Master 
Mix (Invitrogen, Carlsbad, CA, USA) in a QuantStudio 
12  K Flex Real-Time PCR System (Applied Biosystems, 
Foster City, CA, USA). Divergent primer pairs were 
designed to overlap the backspliced junction by using 
Primer3 website (http://prime r3.ut.ee/). Furthermore, 
GAPDH housekeeping gene and convergent primer pairs 
to amplify the host mRNA were designed by Real Time 
PCR tool (IDT, Coralville, IA, USA). Primer sequences 
are listed in Additional file 2: Table S2. At the designing 
stage, verification of primers specificity was carried out 
by PCR tool at the UCSC Genome Browser [15]. After 
amplification, we also checked that RT-qPCR reaction 
had generated a single-peak in the melting curve and a 
single amplicon of the correct size by performing aga-
rose gel electrophoresis. The thermal cycling conditions 
consisted of an initial denaturation step at 95  °C for 
10 min followed by 40 cycles of 15 s at 95 °C and 1 min 
at 60  °C. Expression levels of each corresponding linear 
transcript, GAPDH or convergent amplicon of the host 
gene, was used to normalize circRNA levels [16]. Relative 
expression level of circRNA in a particular sample was 
calculated by the delta delta-CT method, as previously 
described [17]. Non-template reactions were included as 
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negative controls in each run. Finally, qPCR amplicons 
were subjected to Sanger sequencing [18] and checked 
for the presence of the predicted backspliced junctions in 
order to test their circularity.
Functional in silico analysis
Since certain circRNAs may function as sponges seques-
tering miRNAs and, therefore, may be involved in the 
regulation of gene expression, it was interesting to 
explore the potential interactions between differen-
tially expressed circRNAs in stroke and miRNAs. The 
circRNA/microRNA interaction was predicted with 
Arraystar’s home-made miRNA target prediction soft-
ware based on TargetScan & miRanda [19], and the dif-
ferentially expressed circRNAs were annotated in detail 
with the circRNA/miRNA interaction information. Then, 
overrepresented miRNAs (those linked to at least four 
differentially expressed circRNAs) were analyzed by 
DIANA-mirPath v.3 software [20] to predict the underly-
ing pathways.
CircInteractome tool provided a list of miRNAs poten-
tially targeted by the circRNA of interest and mapped 
binding sites for RNA-binding proteins (RBPs) on it [21]. 
Next, DIANA-mirPath v.3 software [20] analyzed the 
pathways in which the outcome miRNAs were involved 
based on TarBase v7.0, microT-CDS v5.0 and TargetScan. 
Kyoto Encyclopedia of Genes and Genomes (KEGG) and 
Gene Ontology (GO) analyses were used to predict cell 
signaling pathways and functions related with the set of 
outcome miRNAs.
Moreover, in order to assess the interactions betweem 
the RBPs predicted to bind a particular differentially 
expressed circRNA, protein list was uploaded to the 
Search Tool for the Retrieval of Interacting Genes 
(STRING) tool (Version 11.0) [22] and filtered for inter-
actions of high confidence (score > 0.7) and PANTHER 
(Protein ANalysis THrough Evolutionary Relationships) 
Classification System (Version 14.1) [23]. Only those 
terms with a FDR-corrected p-value < 0.05 were reported.
Statistical Analysis
Statistical analysis was performed with SPSS 21.0 (IBM, 
Inc., USA). First, adjustment to normal distribution was 
tested for all continuous variables as per one-sample Kol-
gomorov-Smirnov test and the normal quantil-quantil 
(QQ) plots. Data represents the mean ± standard devia-
tion (SD) or the median (interquartile range). In the dis-
covery cohort, univariate analysis of demographic and 
clinical characteristics was performed by ANOVA or 
Kruskall-Wallis test along with Chi square test. In the 
validation cohort, univariate analysis of demographic 
and clinical characteristics was performed by Student 
t-test or U Mann–Whitney test along with Chi square 
test. circRNA expression differences between two groups 
was estimated by Mann–Whitney U test. For all the com-
parisons, significance level was set at p-value < 0.05. SPSS 
21.0 (IBM, Inc., USA) was used to draw graphs.
Results
Differential expression of circRNAs in etiologic stroke 
subtypes
To begin to ask whether circRNAs were differentially 
expressed in ischemic stroke depending on subtype eti-
ology, we performed Arraystar Human circRNA Array 
V2 analysis, which included 13,617 distinct probes for 
human circRNAs, on a target group of 30 patients suffer-
ing from acute ischemic stroke with different etiologies 
according to TOAST classification [2], i.e. 14 cardioem-
bolic, 8 atherotrombotic and 8 undetermined stroke. 
Demographic and clinical characteristics of patients 
included in the discovery cohort are shown in Table  1. 
Normalized intensity values showed similar distribu-
tions of the intensities (expression values) for all samples 
(Additional file 1: Fig. S1).
The main aim of this study was to identify differences 
in circRNA expression between atherotrombotic and 
cardioembolic stroke patients. We found 219 differen-
tially expressed circRNAs (FC ≥ 1.5 and p-value ≤ 0.05) 
in atherotrombotic versus cardioembolic stroke patients 
(Additional file 2: Tables S3 and S4). circRNA expression 
variation between the two compared groups is repre-
sented as volcano plots and scatter plots (Fig. 1a, Addi-
tional file  1: Fig.  S2A). Despite we observed a higher 
number of downregulated (159) than upregulated (60) 
circRNAs in atherotrombotic compared to cardioem-
bolic samples, the best findings in terms of statistical 
significance and magnitude of change were found among 
the upregulated circRNAs. Indeed, 11.7% (7) of upregu-
lated circRNAs showed more than fourfold change in 
expression (Additional file 2: Table S3).
When comparing atherotrombotic versus undeter-
mined strokes, 226 circRNAs were found to be differen-
tially expressed (FC ≥ 1.5 and p-value ≤ 0.05), being 87 
circRNAs upregulated and 139 circRNAs downregulated 
in atherotrombotic compared to undetermined strokes 
(Additional file  2: Tables S5 and S6, Fig.  1b and Addi-
tional file 1: Fig. S2B). In this set, differences were not as 
strong as in the previous comparison of atherotrombotic 
versus cardioembolic strokes, and only one circRNA 
showed expression higher than fourfold change. Finally, a 
very few changes were found when comparing cardioem-
bolic and undetermined strokes, as only 8 circRNAs were 
found to be upregulated and 9 circRNAs were down-
regulated in this comparison (Additional file 2: Table S7, 
Fig. 1c and Additional file 1: Fig. S2C).
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As shown in Fig.  2A, differentially expressed circR-
NAs seem to cluster in chromosomes 1, 2, 3 and 17 for 
the comparison atherotrombotic versus cardioembolic 
stroke (> 15 hits); 1, 2, 7 and 17 for atherotrombotic ver-
sus undetermined (> 15 hits) and 4 and 17 for cardioem-
bolic versus undetermined (> 2.5 hits). With these results 
in mind, circRNAs from chromosome 17, and even 1 and 
2, appear to be important for stroke etiology. In terms of 
distribution by chromosome regions, the number of dif-
ferentially expressed circRNAs that are transcribed from 
protein-coding exons is the most abundant and compa-
rable across downregulated and upregulated circRNAs 
(Fig. 2b). There were only a few intronic, antisense, sense 
overlapping and intergenic type circRNAs.
Validation of differentially expressed circRNAs by RT-qPCR
To validate the differences in circRNA expression, we 
focused on the atherotrombotic versus cardioembolic 
comparison since that was the main goal of our study. 
An expanded cohort which included samples previously 
analyzed in the microarray (n = 50; 25 atherotrombotic 
and 25 cardioembolic samples) was used to this end. 
Next, 3 upregulated and 2 downregulated circRNAs in 
atherotrombotic versus cardioembolic stroke patients 
were selected based on highest fold change and/or lowest 
p-value prioritization (Table 2). Then, we performed RT-
qPCR to amplify and quantify the chosen circRNAs, their 
host mRNAs and GAPDH mRNA levels. Compared to 
the linear transcript, only hsa_circRNA_102488 showed 
a statistically significant change in expression between 
etiology subtypes. hsa_circRNA_102488 is originated 
from the ubiquitin a-52 residue ribosomal protein fusion 
product 1 (UBA52) gene which is located at chromosome 
19 (Fig. 3a). Sanger sequencing confirmed the presence of 
the backsplicing junction between UBA52´ exons 3 and 2 
(Fig. 3b). Mann–Whitney U test revealed that expression 
levels of hsa_circRNA_102488 (alias hsa_circ_0005568) 
were lower for atherotrombotic compared to cardioem-
bolic samples when normalizing to GAPDH mRNA 
(p-value < 0.01) (Fig. 3c), as well as to the corresponding 
UBA52 mRNA (p-value < 0.001) (Fig.  3d). Interestingly, 
we did not found significant differences in UBA52 mRNA 
expression levels between atherotrombotic and cardi-
oembolic stroke samples (Fig. 3e).
Functional in silico analysis of differentially expressed 
circRNAs
In order to explore potential interactions between dif-
ferentially expressed circRNAs in stroke subtypes and 
target miRNAs, a bioinformatics analysis was per-
formed (see “Methods”). First, interactions between 
circRNAs and their target miRNAs were predicted by 
Arraystar’s home-made software. Then, we selected 
the overrepresented miRNAs in the three compari-
sons (those miRNAs linked to at least four differen-
tially expressed circRNAs), and characterized their 
related pathways by DIANA-mirPath (p-value thresh-
old ≤ 0.05). Overrepresented miRNAs were associ-
ated with fatty acid biosynthesis and metabolism, 
lysine degradation, arrhythmogenic right ventricular 
Fig. 1 Volcano‑plots of differential expression of circRNAs for stroke etiology comparisons. Graphs visualize the relationship between fold‑change 
(magnitude of change) in the X axes and statistical significance (which takes both magnitude of change and variability into consideration) in 
the Y axes. A high number of circRNAs are shown as differentially expressed between atherotrombotic versus cardioembolic strokes (a), and 
atherotrombotic versus undetermined strokes (b) whereas cardioembolic versus undetermined strokes show less differences suggesting both 
groups are similar in terms of circRNA expression. The vertical green lines correspond to the threshold of 1.5‑fold up and down, respectively, and the 
horizontal green line represents a p‑value = 0.05. Red points in the plot represent the differentially expressed circRNAs with statistical significance 
which crossed the fold‑change threshold
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cardiomyopathy (ARVC), adrenergic signaling in car-
diomyocytes or hypertrophic cardiomyopathy (HCM) 
as shown by KEGG analysis (p-value threshold < 0.05) 
(Additional file  1: Fig.  S3A). Moreover, these miRNAs 
were linked to cellular nitrogen compound metabolic 
process, homophilic cell adhesion via plasma mem-
brane adhesion molecules, cell adhesion, blood 
coagulation or neurotrophin tyrosine-kinase (TRK) 
receptor signaling pathway in GO analysis (p-value 
threshold < 0.05) (Fig. 4a).
Fig. 2 Distribution by chromosomes (a) and chromosome’s region (b). Differentially expressed circRNA distribution in chromosomes and 
chromosome´s region (exonic, intronic, antisense, sense overlapping and intergenic) for each comparison
Table 2 Deregulated circRNA chosen for qPCR validation
CircRNA deregulated circRNA with greater intensity values in atherotrombotic stroke patients compared with cardioembolic; circRNA_type: the circRNAs are classified 
into 5 types: “exonic”, “intronic”, “antisense”, “sense overlapping” and “intergenic”; FC absolute ratio (no log scale) of normalized intensities between two conditions; 
p-value p-value calculated from unpaired t-test; Annotations, include chromosome position and Gene Symbol
Regulation CircRNA CircRNA type FC (abs) P-value Chromosome position Gene symbol
Up hsa_circRNA_001359 intronic 7.0479384 0.002611197 chr1 169663839 169664181 SELL
hsa_circRNA_103559 exonic 4.8769307 0.035206182 chr3 196118683 196120490 UBXN7
hsa_circRNA_104220 exonic 4.8572966 0.026033314 chr6 150092297 150094305 PCMT1
Down hsa_circRNA_102488 exonic 2.7229035 8.17917E−05 chr19 18684102 18684558 UBA52
hsa_circRNA_104748 exonic 2.3292681 0.001448543 chr9 20907148 20929595 FOCAD
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Regarding the validated circRNA, hsa_cir-
cRNA_102488, CircInteractome tool [21] showed one 
7mer-m8 or 7mer-1a type target site shared by the fol-
lowing miRNAs: hsa-miR-1182, hsa-miR-1299, hsa-
miR-431, hsa-miR-516b, hsa-miR-668 and hsa-miR-766. 
DIANA-mirPath analysis revealed that this set of miR-
NAs converged on the pathways of fatty acid biosynthe-
sis and metabolism, extracellular matrix (ECM)-receptor 
interaction, lysine degradation or arrhythmogenic right 
ventricular cardiomyopathy (ARVC) as shown by KEGG 
analysis (p-value threshold < 0.001 (Additional file  1: 
Fig.  S3B, C). They seemed to have a common function 
as RNA-, ion- and enzyme-binding molecules, a protein 
and nucleic acid binding transcription factor activity 
and to be involved in cellular nitrogen compound meta-
bolic, biosynthetic, cellular protein modification and 
gene expression processes (GO analysis, p-value thresh-
old < 0.05) (Fig. 4b, c).
In addition, up to 10 RBPs sites matching to hsa_cir-
cRNA_102488 were identified by CircInteractome: 3 
for SFRS1, 2 for AGO2, HuR, IGF2BP2 and PTB and 1 
for CAPRIN1, DGCR8, FMRP, IGF2BP1 and LIN28B. 
STRING clustered these RBPs around AGO2 (protein–
protein interaction, PPI, enrichment p-value < 1.0e−16) 
(Additional file  1: Fig.  S4A–C) and PANTHER related 
them to two categories of molecular functions: RNA 
binding and catalytic activity. Moreover, other RBPs 
sites that matched to the hsa_circRNA_102488 flank-
ing regions were identify for EIF4A3 (9 Tags), HNRNPC, 
HuR, U2AF65 and FUS genes. After functional analysis, 
we observed that these RBPs clustered around FUS (PPI 
enrichment p-value < 2.11e−10) and related to catalytic 
activity, IGF2BP1 and IGF2BP3 to binding molecular 
function and ZC3H7B separately but also to catalytic 
activity function (STRING and PANTHER tools) (Addi-
tional file 1: Fig. S4D–F).
A diagram illustrating impact pathways mentioned 
above is shown in Fig. 5.
Discussion
In this study, we identified circRNAs that were differ-
entially expressed in human blood according to stroke 
etiology. The strongest differences were found for the 
comparison between atherotrombotic and cardioem-
bolic stroke. Differentially expressed circRNAs were pre-
dicted to predominantly interact with a set of miRNAs 
involved in stroke-related pathways, including fatty acid 
biosynthesis, lysine degradation, arrhythmogenic right 
ventricular cardiomyopathy (ARVC) or hypertrophic car-
diomyopathy (HCM), among others.
circRNAs are a new class of non-coding RNA mol-
ecules with circular morphology due to the formation 
of a covalent junction between the 3′ and 5′ ends. These 
molecules are generated from a parental (also known as 
Fig. 3 RT‑qPCR validation of hsa_circRNA_102488. a Schematic representation of the UBA52 gene, origin of hsa_circRNA_102488. The graph 
shows the map of hsa_circRNA_102488 which is originated from exons 2 and 3 of its host mRNA (NCBI RefSeq track shown in the UCSC Genome 
Browser). b hsa_circRNA_102488 backsplicing. The Sanger‑Sequencing electropherogram specifies the sequence of the backspliced junction that 
results in the circRNA formation. c–e hsa_circRNA_102488 and UBA52 mRNA expression levels between atherotrombotic vs cardioembolic samples. 
Percentage of hsa_circRNA_102488 expression relative to GAPDH mRNA (c) or UBA52 mRNA (d) is decreased in atherotrombotic with respect to 
cardioembolic stroke patients. However, we found similar expression levels of UBA52 mRNA in atherotrombotic and cardioembolic samples groups 
(e). Error bars: 95% CI. **p‑value < 0.01; ***p‑value < 0.001
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Fig. 4 GO analysis by mirPath v.3. The image shows the heatmaps corresponding to the analysis performed with the overrepresented miRNAs in 
the three comparisons (atherotrombotic‑cardioembolic‑undetermined) by TargetScan (a) and the analysis involving the target miRNAs for hsa_
circRNA_102488 in accordance with molecular function (b, by Tarbase) or biological process (c, by microT‑CDS)
Fig. 5 hsa_circRNA_102488 impact pathways. The cartoon shows miRNAs (in blue) sharing a target site with hsa_circRNA_102488 (in black) and 
the pathways in which they converge (in dark orange), within those associated with the overrepresented miRNAs in the three comparisons (in light 
orange). RBPs sites matching to hsa_circRNA_102488 clustered around AGO2 (in dark green) and RBPs sites that matched to its flanking regions 
clustered around FUS (in light green). ARVC: Arrhythmogenic Right Ventricular Cardiomyopathy; HCM: Hypertrophic Cardiomyopathy
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host) pre-messenger RNA through a particular alterna-
tive splicing process known as backsplicing [24, 25]. The 
covalent bond confers resistance to ribonucleases pre-
venting degradation and making circRNAs very stable 
molecules. Furthermore, circRNAs are expressed in most 
mammalian tissues, particularly in the brain and have 
been also detected in the human blood [26–28]. All these 
characteristics make circRNAs potential biomarkers of 
human diseases and, especially, of neurological diseases.
Indeed, previous reports suggesting the potential role 
of circRNAs as biomarkers or therapeutic targets in neu-
rological conditions, such as multiple sclerosis or epi-
lepsy, have been already published [29–31]. In the stroke 
field, a number of changes in circRNAs expression levels 
have been recently described. In 2017, it was observed 
for the first time that circRNAs are altered in the mouse 
brain after transient focal ischemia [32, 33]. Despite these 
initial observations, as far as we know, a comprehensive 
profiling of circRNAs in human stroke or its relationship 
to stroke etiology has not previously been reported.
In our study, a set of 219 differentially expressed circR-
NAs between atherotrombotic and cardioembolic stroke 
was found in the blood of acute stroke patients. The most 
robust statistical differences were observed among the 60 
circRNAs up-regulated in atherotrombotic compared to 
cardioembolic samples. Most of them tended to cluster 
in chromosome 17 and were of exonic origin, which is 
not surprising since the majority of known circRNA mol-
ecules are exonic and therefore, there is an overrepresen-
tation of exonic circRNAs in the Arraystar microarray.
Even though a large number of circRNAs were shown 
to be differentially expressed in atherotrombotic ver-
sus undetermined stroke samples, there were hardly any 
differences between cardioembolic and undetermined 
strokes. This result suggests that the undetermined 
stroke group may harbor a great proportion of non-
recognized cardioembolic strokes, which is in line with 
current knowledge in the clinical setting. In fact, it has 
been described that some patients with stroke of unde-
termined etiology may have atrial structural or functional 
changes thus increasing the risk of cardioembolism [34].
In recent years, functions of circRNAs are beginning 
to be understood. It has been observed that circRNAs 
can act at different levels of gene regulation, including 
transcription, mRNA splicing or translation. However, 
the best known function so far is the regulation of gene 
expression by acting as miRNA sponges: circRNAs have 
binding sites for specific miRNAs and act by “sequester-
ing” them to prevent miRNAs from exerting translational 
repression. Thus far, a few stroke-related circRNAs act-
ing as miRNA sponges have been observed. circRNA 
DLGAP4 functions as a sponge for miRNA-143 and 
therefore, inhibits miRNA-143 activity. Interestingly, 
overexpression of circRNA DLGAP4 ameliorates neu-
rological deficit and infarct volume after transient focal 
ischemia in a stroke mouse model. circRNA DLGAP4 
seems to significantly attenuate blood–brain barrier 
damage by regulating tight junction protein expression 
and endothelial-mesenchymal transition in endothelial 
cells [35]. Other example of deregulated circRNAs in 
stroke is circRNA Hectd1, which was found to be upreg-
ulated in the brain of mice after transient middle cerebral 
artery occlusion (tMCAO). circRNA HECTD1 partici-
pates in the inhibition of astrocyte activation via macro-
autophagy/autophagy by acting as a sponge for MIR-142 
[36]. Interestingly, circRNA HECTD1 was increased in 
peripheral blood mononuclear cells from acute ischemic 
stroke patients compared to controls and higher levels of 
circRNA HECTD1 were related with stroke recurrence 
[37]. The circRNA TLK1, which acts as an endogenous 
miR-335-3p sponge, has been proved to be detrimental 
in ischemic brain injury. It was increased in the mouse 
brain after tMCAO and knocking down circRNA TLK1 
improve neurological deficits and infarct volume in this 
stroke mouse model. Remarkably, circRNA TLK1 was 
observed to be also elevated in human patients after 
ischemic stroke [38].
In the present study, differentially expressed circR-
NAs were predicted to interact with numerous miR-
NAs. Functional study showed that those miRNAs were 
involved in pathways associated with stroke etiology or 
pathogenesis, such as fatty acids biogenesis, lysine deg-
radation or development of cardiopathy, including ARVC 
and HCM. Elevated levels of free fatty acids have been 
associated with cardioembolic etiology of stroke irre-
spective of the presence of atrial fibrillation [39, 40] and 
predict stroke recurrence in patients with atrial fibrilla-
tion [41]. Although the underlying mechanisms remain 
unclear, fatty acids are major components of epicardial fat 
and it is known that thickness of epicardial fat is related 
with the presence of atrial fibrillation [42]. According to 
that, serum fatty acid binding proteins are proposed as 
biomarkers for atrial fibrillation [43]. However, fatty acids 
seem independent predictors of stroke events so they 
may be directly related to thrombogenesis [39, 40].
Interestingly, lysine degradation pathway showed a 
strong association with overrepresented miRNAs in our 
study. Lysine is an essential aminoacid with pleiotropic 
functions in humans. In addition to proteinogenesis, 
lysine is involved in the crosslinking of collagen peptides, 
the uptake of calcium and iron and is the precursor of 
carnitine, which in turn is essential in the metabolism 
of fatty acids [44]. Lysine degradation differs in brain 
from that of in extracerebral tissues and it is known to be 
regulated by thyroid hormones [45]. For now, its role in 
stroke is not yet well understood. A recent study among 
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hypertensive subjects revealed altered metabolic path-
ways, including lysine degradation, related to incident 
ischemic stroke [46]. Moreover, a metabolomic study 
showed that levels of serum lysine catabolites were low 
in patients at high-risk of suffering ischemic stroke [47].
Despite ARVC is not among the classical embolic 
sources of stroke events, ARVC pathways have been 
recently associated with ischemic stroke in a compre-
hensive long non-coding RNA transcriptomic study [48] 
and this is consistent with our results. HCM is a common 
hereditary cardiomyopathy frequently associated with 
sudden death. It has been described that atrial fibrillation 
with risk for progressive heart failure and embolic stroke 
occurs in 20% of patients with HCM [49].
In this study, we were able to validate hsa_cir-
cRNA_102488 in an expanded cohort of atherotrom-
botic versus cardioembolic strokes. This circRNA is 
formed from the pre-mRNA of UBA52 gene and has a 
456 bp genomic length. hsa_circRNA_102488 was found 
to be highly expressed in brain tissues [27]. No previ-
ous records of the association between UBA52 gene and 
stroke have been reported to our knowledge.
Functional analysis revealed that hsa_circRNA_102488 
harbors a binding site for 6 different miRNAs. Intrigu-
ingly, this set of 6 miRNAs is enriched in pathways 
similar to those found for the overrepresented miRNAs, 
namely fatty acids biogenesis, lysine degradation and 
ARVC. This result suggests that hsa_circRNA_102488 
may be representative of the altered circRNA network 
and its related pathways underlying stroke etiology and 
makes hsa_circRNA_102488 an interesting candidate 
worth to be explored in futures studies.
Among known functions, circRNAs interact with RNA 
binding proteins (RBPs) to influence gene transcription 
and translation [50]. In hsa_circRNA_102488, the analy-
sis revealed RBPs binding sites that cluster around two 
RBPs: argonaute 2 (Ago2) and RNA-binding protein FUS. 
Argonaute 2 is a critical component of the RNA-induced 
silencing complex (RISC) and, as a consequence, a master 
regulator of miRNAs-dependent gene silencing pathway. 
Interestingly, it has been observed that Ago2 accumu-
lates and undergoes hydroxylation following hypoxia, 
thus Ago2 emerges as a major regulator of the pathologi-
cal responses to hypoxia [51]. In fact, stroke substantially 
modifies Ago2-associated miRNA profiles in the brain in 
a stroke rat model [52]. On the other hand, FUS partici-
pates in DNA repair mechanisms [53] and is frequently 
mutated in amyotrophic lateral sclerosis [54]. However, 
no previous works on the role of FUS in stroke has been 
previously reported.
The determination of circRNA as biomarkers in the eti-
ology of stroke would be a great advance in the diagnostic 
process of cerebral vascular diseases. It should be noted 
that circRNAs are especially interesting as biomarkers 
because they represent a gene regulatory mechanism for 
several genes at once and, despite being RNA molecules, 
they are extremely stable. A large part of the study car-
ried out on these patients is aimed to find the cause of 
the stroke, and in up to 25% of cases a clear etiology can-
not be established. The risk factors that predispose to 
presenting an atherothrombotic stroke are widely known 
and current guidelines make general recommendations 
to prevent them. However, patients who remain without 
a specific etiological diagnosis would not benefit from 
these guidelines. Moreover, knowing the cause of stroke 
in a rapid and non-invasive way would help to improve 
secondary prevention and avoid unnecessary studies.
As a discovery study, where typically a large number 
of molecules are measured in a reduced number of sub-
jects, an obvious limitation of this study is the limited 
sample size. Therefore, we should be cautious with our 
conclusions. For the sake of external validity, these find-
ings should be replicated in blood samples of an inde-
pendent cohort of ischemic stroke patients with different 
etiologies.
Conclusions
The present study showed a set of differentially expressed 
circRNAs in peripheral blood from different stroke etio-
logic subtypes. These circRNAs revealed interesting 
pathways underlying stroke etiology, such as fatty acid 
biogenesis or lysine degradation. Due to their molecular 
features, circRNAs may be useful as candidate biomark-
ers for stroke etiology. Large and independent cohort 
studies will be needed to further investigate the role of 
circRNAs as stroke biomarkers.
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